A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

被引：14

作者：

Sekeres, Mikkael A. ^{[1
]}

Schuster, Michael W. ^{[2
]}

Joris, Magalie ^{[3
]}

Krauter, Jurgen ^{[4
]}

Maertens, Johan A. ^{[5
]}

Gyan, Emmanuel ^{[6
]}

Kovacsovics, Tibor ^{[7
]}

Verma, Amit ^{[8
]}

Vyas, Paresh ^{[9
]}

Wang, Eunice S. ^{[10
]}

Ma, Weidong Wendy ^{[11
]}

Zeremski, Mirjana ^{[11
]}

Kudla, Arthur ^{[11
]}

Chan, Geoffrey ^{[11
]}

Zeidan, Amer M. ^{[12
,13
]}

机构：

[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[2] SUNY Stony Brook, Hosp Canc Ctr, Stony Brook, NY USA

[3] CHU Amiens Picardie, Amiens, France

[4] Med Klin Braunschweig GmbH, Dept Internal Med 3, Braunschweig, Germany

[5] UZ Leuven, Leuven, Belgium

[6] CHU Tours, Hop Bretonneau, Tours, France

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Hematol & Oncol, Bronx, NY 10467 USA

[9] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England

[10] Roswell Pk Canc Inst, Buffalo, NY USA

[11] Pfizer Oncol, New York, NY USA

[12] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA

[13] Yale Univ, Yale Canc Ctr, New Haven, CT USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124050

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

177

引用

页数：6

共 50 条

[31] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
Platzbecker, Uwe
Chromik, Joerg
Kroenke, Jan
Handa, Hiroshi
Strickland, Stephen
Miyazaki, Yasushi
Wermke, Martin
Sakamoto, Wataru
Tachibana, Yoshifumi
Taube, Tillmann
Germing, Ulrich
BMC CANCER, 2022, 22 (01)
[32] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
Uwe Platzbecker
Joerg Chromik
Jan Krönke
Hiroshi Handa
Stephen Strickland
Yasushi Miyazaki
Martin Wermke
Wataru Sakamoto
Yoshifumi Tachibana
Tillmann Taube
Ulrich Germing
BMC Cancer, 22
[33] Response to azacitidine is independent of TP53 mutations in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Mueller-Thomas, C.
Rudelius, M.
Wolf, P.
Schanz, J.
Schmidt, B.
Platzbecker, U.
Germing, U.
Peschel, C.
Goetze, K.
LEUKEMIA RESEARCH, 2013, 37 : S73 - S74
[34] Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Mueller-Thomas, Catharina
Rudelius, Martina
Rondak, Ina-Christine
Haferlach, Torsten
Schanz, Julie
Huberle, Christina
Schmidt, Burkhard
Blaser, Rainer
Kremer, Marcus
Peschel, Christian
Germing, Ulrich
Platzbecker, Uwe
Goetze, Katharina
HAEMATOLOGICA, 2014, 99 (10) : E179 - E181
[35] Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Berdeja, Jesus G.
Abaza, Yasmin
Jabbour, Elias
Essell, James
Lyons, Roger M.
Ravandi, Farhad
Maris, Michael
Heller, Brian
DeZern, Amy E.
Babu, Sunil
Wright, David
Anz, Bertrand
Boccia, Ralph
Komrokji, Rami S.
Kuriakose, Philip
Reeves, James
Sekeres, Mikkael A.
Kantarjian, Hagop M.
Ghalie, Richard
Roboz, Gail J.
CANCER, 2017, 123 (06) : 994 - 1002
[36] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
Watts, Justin
Ades, Lionel
Radinoff, Atanas
Arnan Sangerman, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua
Campelo, Maria Diez
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Sekeres, Mikkael A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
[37] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
Freyrie, A.
Reda, G.
Vincenti, D.
Ferla, V.
Orofino, N.
Sciume, M.
Guidotti, F.
Cortelezzi, A.
LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
[38] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Sekeres, Mikkael A.
List, Alan F.
Cuthbertson, David
Paquette, Ronald
Ganetsky, Rebecca
Latham, Deborah
Paulic, Katarina
Afable, Manuel
Saba, Hussain I.
Loughran, Thomas P., Jr.
Maciejewski, Jaroslaw P.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
[39] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
Sallman, David Andrew
Al Malki, Monzr M.
Asch, Adam Steven
Wang, Eunice S.
Jurcic, Joseph G.
Bradley, Terrence J.
Flinn, Ian W.
Pollyea, Daniel Aaron
Kambhampati, Suman
Tanaka, Tiffany N.
Zeidner, Joshua F.
Garcia-Manero, Guillermo
Jeyakumar, Deepa
Gu, Lin
Tan, Anderson
Chao, Mark
O'Hear, Carol Elaine
Lal, Indu
Vyas, Paresh
Daver, Naval Guastad
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
Bengt Rasmussen
Gudrun Göhring
Elsa Bernard
Lars Nilsson
Magnus Tobiasson
Martin Jädersten
Hege Garelius
Ingunn Dybedal
Kirsten Grønbaek
Elisabeth Ejerblad
Fryderyk Lorenz
Max Flogegård
Claus Werenberg Marcher
Annette Öster Fernström
Lucia Cavelier
Elli Papaemmanuil
Freja Ebeling
Astrid Olsnes Kittang
Jan Maxwell Nørgaard
Leonie Saft
Lars Möllgård
Eva Hellström-Lindberg
Leukemia, 2022, 36 : 1436 - 1439

← 1 2 3 4 5 →